^
Association details:
| Biomarker: | HR positive |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Reolysin (pelareorep) (Apoptosis stimulant) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
P3-07-04 A multicenter, single-arm, open-label Phase I study of AN1004 (Pelareorep) oncolytic virus plus paclitaxel in Chinese patients with Hormone receptor-positive and HER2-negative advanced/metastatic breast cancer (REO 026-1)
Published date:
11/22/2022
Excerpt:
Eligible Chinese patients must be female with good performance status (ECOG PS: 0 or 1), have had histopathological diagnosis with HR+/HER2- advanced/metastatic breast cancer...A secondary objective is to evaluate the preliminary activity of AN1004 and PTX combination therapy....intravenous administration of AN1004 plus PTX is safe and well-tolerated in Chinese patients with advanced/metastatic breast cancer, and demonstrates anti-tumor activity.
Secondary therapy:
paclitaxel
